All In Biotech

Drug Trial Radar · NCT07610837

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

May 7, 2026

Primary completion

Jul 7, 2027

Study completion Jul 7, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.

Conditions

  • Liver Fibrosis
  • Hepatic Cirrhosis

Interventions

  • AZD2389Drug

    potent, selective, first-in-class, small molecule oral inhibitor of FAP and is being developed for the treatment of CLDs with advanced hepatic fibrosis including cirrhosis.

  • PlaceboOther

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change in Enhanced Liver Fibrosis (ELF) score from baseline to week 24Time frame: 24 weeks
  2. Reported quantity and severity of adverse events (AEs)Time frame: Up to and including Day 197
  3. Number of participants with observed changes in blood pressure against baseline mmHg valueTime frame: Up to and including Day 197
  4. Number of participants with identified abnormalities in results of 12-lead safety electrocardiograms (ECG)Time frame: Up to and including Day 197
  5. Number of participants with abnormal laboratory results detected in urine samplesTime frame: Up to and including Day 197
  6. Number of participants with observed changes in heart rate (BPM) against baseline valueTime frame: Up to and including Day 197
  7. Number of participants with observed changes in Sp02 oxygen values against baseline measurementTime frame: Up to and including Day 197
  8. Number of participants with observed changes in body temperature against baseline valueTime frame: Up to and including Day 197
  9. Number of participants with observed changes in respiratory rate against baseline valueTime frame: Up to and including Day 197
  10. Number of participants with abnormal laboratory test results detected in blood samplesTime frame: Up to and including Day 197
  11. Number of participants with abnormal laboratory test results detected in blood samplesTime frame: Up to and including Day 197
  12. Number of participants with abnormal laboratory test results detected in blood samplesTime frame: Up to and including Day 197
  13. Number of participants with abnormal laboratory test results detected in blood samplesTime frame: Up to and including Day 197
  14. Number of participants with abnormal laboratory test results detected in blood samplesTime frame: Up to and including Day 197
  15. Number of participants with abnormal laboratory test results detected in blood samplesTime frame: Up to and including Day 197

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona · Recruiting

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Fresno, California · Recruiting

  • Research Site

    Jupiter, Florida · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Port Orange, Florida · Recruiting

  • Research Site

    Kansas City, Missouri · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Las Vegas, Nevada · Recruiting

  • Research Site

    Morehead City, North Carolina · Recruiting

  • Research Site

    Raleigh, North Carolina · Recruiting

  • Research Site

    Westlake, Ohio · Recruiting

  • Research Site

    Yukon, Oklahoma · Recruiting

  • Research Site

    Clarksville, Tennessee · Recruiting

  • Research Site

    Austin, Texas · Recruiting

  • Research Site

    Denison, Texas · Recruiting

  • Research Site

    Georgetown, Texas · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    San Juan, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.